Publications

in peer-reviewed journals

  1. Tarkia M, Saraste A, Saanijoki T, Oikonen V, Vähäsilta T, Strandberg M, Stark C, Tolvanen T, Teräs M, Savunen T, Green MA, Knuuti J, Roivainen A. Evaluation of 68Ga-labelled tracers for PET imaging of myocardial perfusion in pigs. Nucl. Med. Biol. (in press).
  2. Kudomi N, Sipilä H, Autio A, Oikonen V, Liljenbäck H, Tarkia M, Laivola J, Johansson J, Teräs M, Roivainen A. Cross validation of input functions obtained by H215O PET imaging of rat heart and a blood flow-through detector. Mol Imaging Biol. (in press).
  3. Kudomi N, Bucci M, Oikonen V, Silvennoinen M, Kainulainen H, Nuutila P, Iozzo P, Roivainen A. Extraction of input function from rat [18F]FDG PET images. Mol. Imaging Biol. 2011; 13(6): 1241-1249. PubMed (PDF).
  4. Orava J, Nuutila P, Lidell ME, Oikonen V, Noponen T, Viljanen T, Scheinin M, Taittonen M, Niemi T, Enerbäck S, Virtanen KA. Different metabolic responses of human brown adipose tissue to activation by cold and insulin. Cell Metab. 2011; 14(2): 272-279. PubMed (PDF).
  5. Virta JR, Laatu S, Parkkola R, Oikonen V, Rinne JO, Ruutiainen J. Cerebral acetylcholinesterase activity is not decreased in MS patients with cognitive impairment. Mult Scler J. 2011; 17(8): 931-938. PubMed (PDF).
  6. Bucci M, Borra R, Någren K, Maggio R, Tuunanen H, Oikonen V, Del Ry, S, Viljanen T, Taittonen M, Rigazio S, Giannessi D, Parkkola R, Knuuti J, Nuutila P, Iozzo P. Human obesity is characterized by defective fat storage and enhanced muscle fatty acid oxidation, and trimetazidine gradually counteracts these abnormalities. Am. J. Physiol. Endocrinol. Metab. 2011; 301: E105-E112. PubMed (PDF).
  7. Heinonen I, Saltin B, Kemppainen J, Sipilä H, Oikonen V, Nuutila P, Knuuti J, Kalliokoski K, Hellsten Y. Skeletal muscle blood flow and oxygen uptake at rest and during exercise in humans: a PET study with nitric oxide and cyclooxygenase inhibition. Am. J. Physiol. Heart Circ. Physiol. 2011; 300: H1510-H1517. PubMed (PDF, Podcast).
  8. Östberg A, Virta J, Rinne JO, Oikonen V, Luoto P, Någren K, Arponen E, Tenovuo O. Cholinergic dysfunction after traumatic brain injury – preliminary findings from a PET study. Neurology 2011; 76(12): 1046-1050. PubMed (PDF).
  9. Lindholm P, Sutinen E, Oikonen V, Mattila K, Tarkkanen M, Kallajoki M, Aro H, Böhling T, Kivioja A, Elomaa I, Minn H. PET imaging of blood flow and glucose metabolism in localized musculoskeletal tumors of the extremities. Nucl. Med. Biol. 2011; 38: 295-300. (PDF).
  10. Alakurtti K, Aalto S, Johansson JJ, Någren K, Tuokkola T, Oikonen V, Laine M, Rinne JO. Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography. J. Cereb. Blood Flow Metab. 2011; 31: 155-165. PDF
  11. Karmi A, Iozzo P, Viljanen A, Hirvonen J, Fielding BA, Virtanen K, Oikonen V, Kemppainen J, Viljanen T, Guiducci L, Haaparanta-Solin M, Någren K, Solin O, Nuutila P. Increased brain fatty acid uptake in metabolic syndrome. Diabetes 2010; 59(9): 2171-2177. PDF
  12. Heinonen I, Kemppainen J, Kaskinoro K, Peltonen JE, Borra R, Lindroos M, Oikonen V, Nuutila P, Knuuti J, Boushel R, Kalliokoski KK. Regulation of human skeletal muscle perfusion and its heterogeneity during exercise in moderate hypoxia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010; 299(1):R72-R79. PDF
  13. Heinonen I, Kemppainen J, Kaskinoro K, Peltonen JE, Borra R, Lindroos MM, Oikonen V, Nuutila P, Knuuti J, Hellsten Y, Boushel R, Kalliokoski KK. Comparison of exogenous adenosine and voluntary exercise on human skeletal muscle perfusion and perfusion heterogeneity. J. Appl. Physiol. 2010; 108: 378-386. PDF
  14. Hirvonen J, Kailajärvi M, Haltia T, Koskimies S, Någren K, Virsu P, Oikonen V, Sipilä H, Ruokoniemi P, Virtanen K, Scheinin M, Rinne JO. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-Deprenyl-D2: A dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin. Pharmacol. Ther. 2009; 85(5): 506-512. PDF [IF2007=8.033]
  15. Roivainen A, Någren K, Hirvonen J, Oikonen V, Virsu P, Tolvanen T, Rinne J. Whole-body distribution and metabolism of [N-methyl-11C](R)-1-(2-chlorophenyl)-N-(1-methylpropyl)-3-isoquinolinecarboxamide in humans; an imaging agent for in vivo assessment of peripheral benzodiazepine receptor activity with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2009; 36(4): 671-682. PDF [IF2007=4.101]
  16. Kudomi N, Koivuviita N, Liukko KE, Oikonen VJ, Tolvanen T, Iida H, Tertti R, Metsärinne K, Iozzo P, Nuutila P. Parametric renal blood flow imaging using [15O]H2O and PET. Eur. J. Nucl. Med. Mol. Imaging 2009; 36(4): 683-691. PDF [IF2007=4.101]
  17. Hirvonen J, Aalto S, Hagelberg N, Maksimow A, Ingman K, Oikonen V, Virkkala J, Någren K, Scheinin H. Measurement of central μ-opioid receptor binding in vivo with PET and [11C]carfentanil: a test-retest study in healthy subjects. Eur. J. Nucl. Med. Mol. Imaging 2009 ;36(2): 275-286. PDF [IF2007=4.101]
  18. Laitio RM, Långsjö JW, Aalto S, Kaisti KK, Salmi E, Maksimow A, Aantaa R, Oikonen V, Viljanen T, Parkkola R, Scheinin H. The effects of Xenon anesthesia on the relationship between cerebral glucose metabolism and blood flow in healthy subjects: a positron emission tomographic study. Anesth. Analg. 2009; 108(2): 593-600. PDF [IF2007=2.214]
  19. Heinonen I, Nesterov SV, Liukko K, Kemppainen J, Någren K, Luotolahti M, Virsu P, Oikonen V, Nuutila P, Kujala UM, Kainulainen H, Boushel R, Knuuti J, Kalliokoski KK. Myocardial blood flow and adenosine A2A receptor density in endurance athletes and untrained men. J. Physiol. 2008; 586(Pt 21): 5193-5202. PDF [IF2007=4.580]
  20. Salmi E, Aalto S, Hirvonen J, Långsjö JW, Maksimow AT, Oikonen V, Metsähonkala L, Virkkala J, Någren K, Scheinin H. Measurement of GABAA receptor binding in vivo with [11C]flumazenil: A test-retest study in healthy subjects. Neuroimage 2008; 41(2): 260-269. PDF [IF2007=5.457]
  21. Hirvonen J, Johansson J, Teräs M, Oikonen V, Lumme V, Virsu P, Roivainen A, Någren K, Halldin C, Farde L, Hietala J. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J. Cereb. Blood Flow Metab. 2008; 28(5): 1059-1069. PDF [IF2007=5.147]
  22. Slimani L, Kudomi N, Oikonen V, Järvisalo M, Kiss J, Naum A, Borra R, Viljanen A, Ferrannini E, Savunen T, Nuutila P, Iozzo P. Quantification of liver perfusion with [15O]H2O-PET and its relationship with glucose metabolism and substrate levels. J. Hepatol. 2008; 48: 974-982. PDF [IF2007=6.642]
  23. Salmi E, Laitio RM, Aalto S, Maksimow AT, Långsjö JW, Kaisti KK, Aantaa R, Oikonen V, Metsähonkala L, Någren K, Korpi ER, Scheinin H. Xenon does not affect γ-aminobutyric acid type A receptor binding in humans. Anesth. Analg. 2008; 106(1): 129-134. PDF [IF2006=2.131, IF2007=2.214]
  24. Kemppainen NM, Aalto S, Karrasch M, Någren K, Savisto N, Oikonen V, Viitanen M, Parkkola R, Rinne JO. Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild AD. Ann. Neurol. 2008; 63(1): 112-118. PDF [IF2006=8.051, IF2007=8.813]
  25. Liukko KE, Oikonen VJ, Tolvanen TK, Virtanen KA, Viljanen AP, Sipilä HT, Nuutila P, Iozzo P. Non-invasive estimation of subcutaneous and visceral adipose tissue blood flow by using [15O]H2O PET with image derived input functions. Open Med. Imaging J. 2007; 1: 7-13. PDF available from Bentham Open.
  26. Wallius E, Nyman M, Oikonen V, Hietala J, Ruotsalainen U. Voxel-based NK1 receptor occupancy measurements with [18F]SPA-RQ and positron emission tomography: A procedure for assessing errors from image reconstruction and physiological modeling. Mol. Imaging Biol. 2007; 9(5):284-294. PDF [IF2006=2.961]
  27. Laitio RM, Kaisti KK, Långsjö JW, Aalto S, Salmi E, Maksimow A, Aantaa R, Oikonen V, Sipilä H, Parkkola R, Scheinin H. Effects of Xenon anesthesia on cerebral blood flow in humans: A positron emission tomography study. Anesthesiology 2007; 106(6): 1128-1133. PDF [IF2006=4.207]
  28. Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007; 68(19): 1603-1606. PDF [IF2006=5.690, IF2005=4.947]
  29. Naum A, Tuunanen H, Engblom E, Oikonen V, Sipilä H, Iozzo P, Nuutila P, Knuuti J. Simultaneous evaluation of myocardial blood flow, cardiac function and lung water content using [15O]water and positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2007; 34(4): 563-572. PDF [IF2006=4.041, IF2005=3.883].
  30. Hirvonen J, Kajander J, Allonen T, Oikonen V, Någren K, Hietala J. Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-11C]WAY-100635 - Considerations on the validity of cerebellum as a reference region. J. Cereb. Blood Flow Metab. 2007; 27(1): 185-195. PDF [IF2006=4.843, IF2005=4.786]
  31. Havu-Aurén K, Kiiski J, Lehtiö K, Eskola O, Kulvik M, Vuorinen V, Oikonen V, Vähätalo J, Jääskeläinen J, Minn H. Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2 -related schwannoma and meningioma studied with PET. Eur. J. Nucl. Med. Mol. Imaging 2007; 34(1): 87-94. PDF [IF2006=4.041, IF2005=3.883].
  32. Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO. Voxel based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006;67(9): 1575-1580 PDF [IF2006=5.690, IF2005=4.947]
  33. Slimani L, Oikonen V, Hällsten K, Savisto N, Knuuti J, Nuutila P, Iozzo P. Exercise restores skeletal muscle glucose delivery but not insulin-mediated glucose transport and phosphorylation in obese subjects. J. Clin. Endocrinol. Metab. 2006; 91(9): 3394-3403. PDF [IF2006=5.799, IF2005=6.020].
  34. Iozzo P, Gastaldelli A, Järvisalo MJ, Kiss J, Borra R, Buzzigoli E, Viljanen A, Naum G, Viljanen T, Oikonen V, Knuuti J, Savunen T, Salvadori PA, Ferrannini E, Nuutila P. 18F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study. J. Nucl. Med. 2006; 47: 1016-1022. PDF [IF2006=4.986, IF2005=4.648]
  35. Pärkkä JP, Niemi P, Saraste A, Koskenvuo JW, Komu M, Oikonen V, Toikka JO, Kiviniemi TO, Knuuti J, Sakuma H, Hartiala JJ. Comparison of MRI and positron emission tomography in measuring myocardial perfusion reserve in healthy humans. Magn. Reson. Med. 2006; 55(4): 772-779. PDF [IF2006=3.427, IF2005=3.508]
  36. Ingman K, Hagelberg N, Aalto S, Någren K, Juhakoski A, Karhuvaara S, Kallio A, Oikonen V, Hietala J, Scheinin H. Prolonged central μ-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 2005; 30: 2245-2253. PDF [IF2004=4.941]
  37. Naum A, Laaksonen MS, Tuunanen H, Oikonen V, Teräs M, Kemppainen J, Järvisalo MJ, Nuutila P, Knuuti J. Motion detection and correction for O-15 water dynamic myocardial PET perfusion studies. Eur. J. Nucl. Med. Mol. Imaging 2005; 32(12): 1378-1383. PDF [IF2004=3.935].
  38. Hietala J, Nyman MJ, Eskola O, Laakso A, Grönroos T, Oikonen V, Bergman J, Haaparanta M, Forsback S, Marjamäki P, Lehikoinen P, Goldberg M, Burns D, Hamill T, Eng W-S, Coimbra A, Hargreaves R, Solin O. Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol. Imaging Biol. 2005; 7(4): 262-272. PDF
  39. Kemppainen J, Aalto S, Fujimoto T, Kalliokoski KK, Långsjö J, Oikonen V, Rinne J, Nuutila P, Knuuti J. High intensity exercise decreases global brain glucose uptake in humans. J. Physiol. 2005; 568: 323-332. PDF [IF2004=4.346]
  40. Långsjö JW, Maksimow A, Salmi E, Kaisti KK, Aalto S, Oikonen V, Hinkka S, Aantaa R, Sipilä H, Viljanen T, Parkkola R, Scheinin H. S-Ketamine anesthesia increases cerebral blood flow in excess to the metabolic needs in humans. Anesthesiology 2005; 103: 258-268. PDF [IF2004=4.055]
  41. Salmi E, Kaisti KK, Metsähonkala L, Oikonen V, Aalto S, Någren K, Hinkka S, Hietala J, Korpi ER, Scheinin H. Sevoflurane and propofol increase 11C-flumazenil binding to gamma-aminobutyric acidA receptors in humans. Anesth. Analg. 2004; 99: 1420-1426. PDF [IF2003=2.210]
  42. Iozzo P, Takala T, Oikonen V, Bergman J, Grönroos T, Ferrannini E, Nuutila P, Knuuti J. Effect of training status on regional disposal of circulating free fatty acids in the liver and skeletal muscle during physiological hyperinsulinemia. Diabetes Care 2004; 27: 2172-2177. PDF [IF2003=7.501]
  43. Iozzo P, Lautamäki R, Geisler F, Virtanen KA, Oikonen V, Haaparanta M, Yki-Järvinen H, Ferrannini E, Knuuti J, Nuutila P. Non-esterified fatty acids impair insulin-mediated glucose uptake and disposition in the liver. Diabetologia 2004; 47: 1149-1156. PDF [IF2003=5.689]
  44. Iozzo P, Turpeinen AK, Takala T, Oikonen V, Bergman J, Grönroos T, Ferrannini E, Nuutila P, Knuuti J. Defective liver disposal of free fatty acids in patients with impaired glucose tolerance. J. Clin. Endocrinol. Metab. 2004; 89: 3496-3502. PDF [IF2003=5.873]
  45. Lehtiö K, Eskola O, Viljanen T, Oikonen V, Grönroos T, Sillanmäki L, Grénman R, Minn H. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int. J. Radiation Oncology Biol. Phys. 2004; 59: 971-982. PDF [IF2003=4.285]
  46. Långsjö JW, Salmi E, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V, Viljanen T, Kurki T, Silvanto M, Scheinin H. Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. Anesthesiology 2004; 100: 1065-1071. PDF [IF2003=3.503]
  47. Hagelberg N, Aalto S, Kajander J, Oikonen V, Hinkka S, Någren K, Hietala J, Scheinin H. Alfentanil increases cortical dopamine D2/D3 receptor binding in healthy subjects. Pain 2004; 109: 86-93. PDF [IF2003=4.556]
  48. Långsjö JW, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V, Sipilä H, Kurki T, Silvanto M, Scheinin H. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003; 99: 614-623. PDF [IF2002=3.470]
  49. Kaisti KK, Långsjö JW, Aalto S, Oikonen V, Sipilä H, Teräs M, Hinkka S, Metsähonkala L, Scheinin H. Effects of sevoflurane, propofol, and adjunct nitrous oxide on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003; 99: 603-613. PDF [IF2002=3.470]
  50. Hirvonen J, Aalto S, Lumme V, Någren K, Kajander J, Vilkman H, Hagelberg N, Oikonen V, Hietala J. Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride. Nucl. Med. Commun. 2003; 24: 1207-1214. PDF [IF2002=1.127]
  51. Iozzo P, Turpeinen AK, Takala T, Oikonen V, Solin O, Ferrannini E, Nuutila P, Knuuti J. Liver uptake of free fatty acids in vivo in humans as determined with 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid and PET. Eur. J. Nucl. Med. Mol. Imaging 2003; 30: 1160-1164. PDF [IF2002=3.568]
  52. Iozzo P, Hällsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, Solin O, Lönnqvist F, Ferrannini E, Knuuti J, Nuutila P. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care 2003; 26: 2069-2074. PDF [IF2002=5.477]
  53. Iozzo P, Geisler F, Oikonen V, Mäki M, Takala T, Solin O, Ferrannini E, Knuuti J, Nuutila P. Insulin stimulates liver glucose uptake in humans: an 18F-FDG PET study. J. Nucl. Med. 2003; 44: 682-689. PDF [IF2002=4.587]
  54. Iozzo P, Hällsten K, Oikonen V, Virtanen KA, Kemppainen J, Solin O, Ferrannini E, Knuuti J, Nuutila P. Insulin-mediated hepatic glucose uptake is impaired in type 2 diabetes: evidence for a relationship with glycemic control. J. Clin. Endocrinol. Metab. 2003; 88: 2055-2060. PDF [IF2002=5.199]
  55. Hällsten K, Yki-Järvinen H, Peltoniemi P, Oikonen V, Takala T, Kemppainen J, Laine H, Bergman J, Bolli GB, Knuuti J, Nuutila P. Insulin- and exercise-stimulated skeletal muscle blood flow and glucose uptake in obese men. Obesity Res. 2003; 11: 257-265. PDF [IF2002=3.025]
  56. Lehtiö K, Oikonen V, Nyman S, Grönroos T, Roivainen A, Eskola O, Minn H. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur. J. Nucl. Med. Mol. Imaging 2003; 30: 101-108. PDF [IF2002=3.568]
  57. Rinne JO, Kaasinen V, Järvenpää T, Någren K, Roivainen A, Yu M, Oikonen V, Kurki T. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2003; 74: 113-115. PDF [IF2002=2.939]
  58. Kaasinen V, Någren K, Järvenpää T, Roivainen A, Yu M, Oikonen V, Kurki T, Rinne JO. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J. Clin. Psychopharmacol. 2002; 22: 615-620. PDF [IF2000=5.052]
  59. Tolvanen T, Lehtiö K, Kulmala J, Oikonen V, Eskola O, Bergman J, Minn H. 18F-fluoroerythronitroimidazole radiation dosimetry in cancer studies. J. Nucl. Med. 2002; 43: 1674-1680. PDF [IF2000=3.617]
  60. Takala TO, Nuutila P, Pulkki K, Oikonen V, Grönroos T, Savunen T, Vähäsilta T, Luotolahti M, Kallajoki M, Bergman J, Forsback S, Knuuti J. 14(R,S)-[18F]Fluoro-6-thia-heptadecanoic acid as a tracer of free fatty acid uptake and oxidation in myocardium and skeletal muscle. Eur. J. Nucl. Med. 2002; 29:1617-1622. PDF [IF2000=3.772]
  61. Kaisti KK, Metsähonkala L, Teräs M, Oikonen V, Aalto S, Jääskeläinen S, Hinkka S, Scheinin H. Effects of surgical levels of propofol and sevoflurane anesthesia on cerebral blood flow in healthy subjects studied with positron emission tomography. Anesthesiology 2002; 96:1358-1370. PDF [IF2000=3.439]
  62. Lehtiö K, Oikonen V, Grönroos T, Eskola O, Kalliokoski K, Bergman J, Solin O, Grénman R, Nuutila P, Minn H. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [15O]H2O and [18F]fluoroerythronitroimidazole PET. J. Nucl. Med. 2001; 42:1643-1652. PDF [IF2000=3.617]
  63. Peltoniemi P, Yki-Järvinen H, Laine H, Oikonen V, Rönnemaa T, Kalliokoski K, Raitakari O, Knuuti J, Nuutila P. Evidence for spatial heterogeneity in insulin- and exercise-induced increases in glucose uptake: studies in normal subjects and patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 2001; 86:5525-5533. PDF [IF2000=5.447]
  64. Bertoldo A, Peltoniemi P, Oikonen V, Knuuti J, Nuutila P, Cobelli C. Kinetic modeling of [18F]FDG in skeletal muscle by PET: a four-compartment five-rate-constant model. Am. J. Physiol. Endocrinol. Metab. 2001; 281:E524-E536 PDF [IF2000=3.183]
  65. Peltoniemi P, Yki-Järvinen H, Oikonen V, Oksanen A, Takala TO, Rönnemaa T, Erkinjuntti M, Knuuti MJ, Nuutila P. Resistance to exercise-induced increase in glucose uptake during hyperinsulinemia in insulin-resistant skeletal muscle of patients with type 1 diabetes. Diabetes 2001; 50:1371-1377. PDF [IF2000=7.715]
  66. Kalliokoski K, Oikonen V, Takala TO, Sipilä H, Knuuti J, Nuutila P. Enhanced oxygen extraction and reduced flow heterogeneity in exercising muscle in endurance-trained men. Am. J. Physiol. Endocrinol. Metab. 2001; 280:E1015-E1021 PDF [IF2000=3.183]
  67. Kalliokoski KK, Kuusela TA, Nuutila P, Tolvanen T, Oikonen V, Teräs M, Takala TES, Knuuti J. Perfusion heterogeneity in human skeletal muscle - fractal analysis of PET data. Eur. J. Nucl. Med. 2001; 28:450-456. PDF [IF2000=3.772]
  68. Ruottinen HM, Niinivirta M, Bergman J, Oikonen V, Solin O, Eskola O, Eronen E, Sonninen P, Rinne UK. Detection of response to COMT inhibition in FDOPA PET in advanced PD requires prolonged imaging. Synapse 2001; 40:19-26. PDF [IF2000=3.402]
  69. Nuutila P, Peltoniemi P, Oikonen V, Larmola K, Kemppainen J, Takala T, Sipilä H, Oksanen A, Ruotsalainen U, Bolli GB, Yki-Järvinen H. Enhanced stimulation of glucose uptake by insulin increases exercise-stimulated glucose uptake in skeletal muscle in humans: studies using [15O]O2, [15O]H2O, [18F]fluoro-deoxy-glucose, and positron emission tomography. Diabetes 2000; 49:1084-1091. Free PDF [IF2000=7.715]
  70. Kaasinen V, Ruottinen HM, Någren K, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C]raclopride and [11C]N-methylspiperone. J. Nucl. Med. 2000; 41: 65-70. PDF [IF2000=3.617]
  71. Kaasinen V, Någren K, Hietala J, Oikonen V, Vilkman H, Farde L, Halldin C, Rinne JO. Extrastriatal Dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 2000;54:1482-1487. PDF [IF2000=4.781]
  72. Lamusuo S, Pitkänen A, Jutila L, Ylinen A, Partanen K, Kälviäinen R, Ruottinen H, Oikonen V, Någren K, Lehikoinen P, Vapalahti M, Vainio P, Rinne JO. [11C]Flumazenil binding in the medial temporal lobe epilepsy: correlation with hippocampal MR volumetry, T2 relaxometry and neuropathology. Neurology 2000; 54:2252-2260. PDF [IF2000=4.781]
  73. Peltoniemi P, Lönnroth P, Laine H, Oikonen V, Tolvanen T, Grönroos T, Strindberg L, Knuuti J, Nuutila P. Lumped constant for [18F]fluorodeoxyglucose in skeletal muscles of obese and nonobese humans. Am. J. Physiol. 2000; 279:E1122-1130. PDF [IF2000=3.183]
  74. Vilkman H, Kajander J, Någren K, Oikonen V, Syvälahti E, Hietala J. Measurement of extrastriatal D2-like receptor binding with [11C]FLB 457 - a test-retest analysis. Eur. J. Nucl. Med. 2000; 27:1666-1673. PDF [IF2000=3.772]
  75. Takala TO, Nuutila P, Katoh C, Luotolahti M, Bergman J, Mäki M, Oikonen V, Ruotsalainen U, Grönroos T, Haaparanta M, Kapanen J, Knuuti J. Myocardial blood flow, oxygen consumption, and fatty acid uptake in endurance athletes during insulin stimulation. Am. J. Physiol. 1999; 277: E585-E590. PDF [IF1999=2.980]
  76. Rinne JO, Bergman J, Ruottinen H, Haaparanta M, Eronen E, OikonenV, Sonninen P, Solin O. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease. Synapse 1999; 31: 119-124. PDF [IF1999=3.245]
  77. Laine H, Knuuti J, Ruotsalainen U, Utriainen T, Oikonen V, Raitakari M, Luotolahti M, Kirvelä O, Vicini P, Cobelli C, Nuutila P, Yki-Järvinen H. Preserved relative dispersion but blunted stimulation of mean flow, absolute dispersion, and blood volume by insulin in skeletal muscle of patients with essential hypertension. Circulation 1998; 97: 2146-2153. PDF [IF1999=9.903]
  78. Mäki MT, Haaparanta M, Nuutila P, Oikonen V, Luotolahti M, Eskola O, Knuuti JM. Free fatty acid uptake in the myocardium and skeletal muscle using [18F]fluoro-6-thia-heptadecanoic acid. J. Nucl. Med. 1998; 39: 1320-1327. PDF [IF1999=3.326]
  79. Ruotsalainen U, Raitakari M, Nuutila P, Oikonen V, Sipilä H, Teräs M, Knuuti MJ, Bloomfield PM, Iida H. Quantitative blood flow measurement of skeletal muscle using oxygen-15-water and PET. J. Nucl. Med. 1997; 38: 314-319. PDF [IF1999=3.326]
  80. Malminiemi K, Laine H, Knuuti MJ, Ruotsalainen U, Oikonen V, Haaparanta M, Nuutila P. Acute effects of celiprolol on muscle blood flow and insulin sensitivity. Eur. J. Clin. Pharmacol. 1997; 52: 19-26. PDF [IF1999=1.771]
  81. Ruottinen HM, Rinne JO, Haaparanta M, Solin O, Bergman J, Oikonen VJ, Järvelä I, Santavuori P. [18F]Fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis. J. Neurol. Neurosurg. Psychiatry 1997; 62: 622-625. PDF [IF1999=2.735]
  82. Salonen I, Hietala J, Laihinen A, Lehikoinen P, Leino L, Någren K, Ruotsalainen U, Oikonen V, Tuokkola T, Näntö V. A PET study on the acute effect of ethanol on striatal D2 dopamine receptors with [11C]raclopride in healthy males. Hum. Psychopharmacol. Clin. Exp. 1997; 12: 145-152. PDF [IF1999=0.609]
  83. Ruottinen H, Rinne JO, Oikonen VJ, Bergman JR, Haaparanta MT, Solin OH, Ruotsalainen UH, Rinne UK. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction. Synapse 1997; 27: 336-346. PDF [IF1999=3.245]
  84. Raitakari M, Nuutila P, Ruotsalainen U, Laine H, Teräs M, Iida H, Mäkimattila S, Utriainen T, Oikonen V, Sipilä H, Haaparanta M, Solin O, Wegelius U, Knuuti J, Yki-Järvinen H. Evidence for dissociation of insulin stimulation of blood flow and glucose uptake in human skeletal muscle. Studies using [15O]H2O, [18F]fluoro-2-deoxy-D-glucose, and positron emission tomography. Diabetes 1996; 45: 1471-1477. (abstract in PubMed) [IF1999=9.019]
  85. Ruottinen HM, Rinne JO, Ruotsalainen UH, Bergman JR, Oikonen VJ, Haaparanta MT, Solin OH, Laihinen AO, Rinne UK. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J. Neural Transm. [P-D Sect] 1995; 10: 91-106. PDF [IF1999=1.688]
  86. Laihinen AO, Rinne JO, Någren KÅ, Lehikoinen PK, Oikonen VJ, Ruotsalainen UH, Ruottinen HM, Rinne UK. PET studies on brain monoamine transporters with carbon-11-β-CIT in Parkinson's disease. J. Nucl. Med. 1995; 36: 1263-1267. PDF [IF1999=3.326]
  87. Rinne JO, Laihinen A, Ruottinen H, Ruotsalainen U, Någren K, Lehikoinen P, Oikonen V, Rinne UK.Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride. J. Neurol. Sci. 1995; 132: 156-161. PDF [IF1999=1.685]
  88. Laihinen AO, Rinne JO, Ruottinen HM, Någren KÅ, Lehikoinen PK, Oikonen VJ, Ruotsalainen UH, Rinne UK. PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756. J. Nucl. Med. 1994; 35: 1916-1920. PDF [IF1999=3.326]
  89. Rinne JO, Hietala J, Ruotsalainen U, Säkö E, Laihinen A, Någren K, Lehikoinen P, Oikonen V, Syvälahti E. Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride. J. Cereb. Blood Flow Metab. 1993; 13: 310-314. PDF (PubMed) [IF1999=5.714]